Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy

AIDS

Volumn 14, Issue 7, 2000, Pages 807-812

  Barreiro, Pablo ^a   Soriano, Vincent ^a,c   Blanco, Francisco ^a   Casimiro, César ^a   De La Cruz, Juan José ^b   González Lahoz, Juan ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c NONE   (Spain)

Author keywords

Highly active antiretroviral therapy (HAART); Lipodystrophy; Nevirapine; Side effects; Viral load

Indexed keywords

CD4 ANTIGEN; CHOLESTEROL; DIDANOSINE; LAMIVUDINE; LIPID; NEVIRAPINE; PROTEINASE INHIBITOR; STAVUDINE; TRIACYLGLYCEROL; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BODY BUILD; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LIPID BLOOD LEVEL; LIPODYSTROPHY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LIPODYSTROPHY; MALE; MIDDLE AGED; NEVIRAPINE; QUALITY OF LIFE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; VIRAL LOAD;

EID: 0034106517     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200005050-00006     Document Type: Article

References (27)

1. 1. Mouton Y, Alfandari S, Valette M. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. AIDS 1997, 11:F101-F106.
2. 2. Van Roon E, Verzijl J, Juttmann J, Lenderink A, Blans M, Egberts A. Incidence of discontinuation of highly active antiretroviral combination therapy (HAART) and its determinants. J Acquir Immune Defic Syndr Hum Retrovirol 1999, 20:290-294.
3. 3. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insuline resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12: F51-F58.
4. 4. Carr A, Samaras K, Thorisdottir A, Kaufmann G, Chisholm D, Cooper D. Diagnosis, prediction, and natural course of HV-1 protease inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353: 2093-2099.
5. 5. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation 1993, 89:1333-1445.
6. 6. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabet Care 1998, 21: S5-S19.
7. 7. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998, 51:1328.
8. 8. Behrens G, Schmidt H, Meyer D, et al. Vascular complications associated with HIV protease inhibitors. Lancet 1998, 351:1958.
9. 9. Burchfield C, Laws A, Benfante R, et al. Combined effects of HDL cholesterol, triglyceride and total cholesterol concentrations on 18-year risk of atheroesclerotic disease. Circulation 1995, 92:1430-1436.
10. 10. Lo J, Mulligan K, Tai V, et al. 'Buffalo hump' in men with HIV-1 infection. Lancet 1998, 351:867-870.
11. 11.Herry I, Bernard L, de Truchis P, Perrone C. Hypertrophy of the breasts in a patient treated with indinavir. Clin Infect Dis 1997, 25:937-938.
12. 12. Viraben R, Aquilina C. Indinavir-associated lipodystrophy. AIDS 1998, 12:F37-F39.
13. 13. Miller K, Jones E, Yanovski J, et al. Visceral abdominal-fat accumulation associated with the use of indinavir. Lancet 1998, 351:871-815.
14. 14. Havlir D, Marschner I, Hirsch M, et al. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple drug therapy. N Engl J Med 1998, 339:1261-1268.
15. 15. Pialoux G, Raffi F, Brun-Vezinet F, et al. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine and indinavir in previously untreated HIV-1-infected patients. N Engl J Med 1998, 339:1269-1276.
16. 16. Reijers M, Weverling G, Jurriaans S, et al. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet 1998, 352:185-190.
17. 17. Martínez E, Conget I, Lozano L, Casamitjana R, Gatell J. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999, 13:805-810.
18. 18. Ruiz L, Bonjoch A, Paredes R, et al. A multicenter, randomized, open-label, comparative trial of the clinical benefit of switching the protease inhibitor by nevirapine in HAART-experienced patients suffering lipodystrophy. Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, January-February 1999 [abstract LB14].
19. 19. Moyle G, Baldwin C, Dent N, Cometis S, Gazzard D. Management of protease inhibitor-associated lipodystrophy by substitution with efavirenz in virologically controlled HIV + persons. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 1999 [abstract 2064].
20. 20. Muñoz V, Casado JL, Moreno A, et al. Persistent viral suppression after switching a protease inhibitor-containing regimen to a nonnucleoside reverse transcriptase inhibitor-based therapy (BEGIN Study). 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 1999 [abstract 2195].
21. 21. Rey D, Hovi R, Partisani M, et al. Efavirenz as a substitute for protease inhibitors in HIV-infected patients on triple-drug therapy with plasma viral load below 20 cop/ml. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 1999 [abstract 2196].
22. 22. Raffi F, Bonnet B, Esnault J, et al. Switch from PI to once daily NNRTI in HIV-infected patients maintaining undetectable plasma viral loads on PI-containing regimens: The Maintavir study. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 1999 [abstract 2198].
23. 23. Stein D, Korvick J, Vermund S. CD4+ cell enumeration for prediction of clinical course of HIV disease: a review. J Infect Dis 1992, 165:352-363.
24. 24. Cleeman J. Detection and evaluation of dyslipoproteinemia. Endocrinol Metab Clin North America 1998, 27:597-611.
25. 25. Cohen S, Hassan S, Lapointe B, Mount B. Quality of life in HIV disease as measured by the McGill Quality of Life Questionnaire. AIDS 1996, 10:1421-1427.
26. 26. Ruiz L, van Lunzen J, Arno A, et al. Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue. AIDS 1999, 13:F1-F8.
27. 27. De Mendoza C, Soriano V, Rodriguez-Rosado R, González-Lahoz J. Higher antiviral activity of antiretroviral regimens including protease inhibitors. AIDS 1999, 13:998-999.